IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression

Neuro-Oncology

Volumn 18, Issue 10, 2016, Pages 1402-1412

  Zhang, Xiaoran ^a   Rao, Aparana ^b   Sette, Paola ^b   Deibert, Christopher ^b   Pomerantz, Alexander ^g   Kim, Wi Jin ^a   Kohanbash, Gary ^c   Chang, Yigang ^b   Park, Yongseok ^d   Engh, Johnathan ^b   Choi, Jaehyuk ^e   Chan, Timothy ^f   Okada, Hideho ^c   Lotze, Michael ^b   Grandi, Paola ^b   Amankulor, Nduka ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

glioma; IDH mutation; immune escape; immunotherapy; Natural Killer cells; NKG2D ligands

Indexed keywords

DECITABINE; ISOCITRATE DEHYDROGENASE; NATURAL KILLER CELL RECEPTOR NKG2D; ANTINEOPLASTIC AGENT; AZACITIDINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; SIGNAL PEPTIDE; TRANSCRIPTOME; ULBP2 PROTEIN, HUMAN;

ARTICLE; ASTROCYTE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOLYSIS; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC DATABASE; GENETIC ENGINEERING; GLIOMA; GLIOMA STEM CELL; HUMAN; HUMAN CELL; IDH GENE; IMMUNOSURVEILLANCE; NATURAL KILLER CELL; NKG2D GENE; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BRAIN TUMOR; DNA METHYLATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MUTATION; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR ESCAPE;

ANTINEOPLASTIC AGENTS; AZACITIDINE; BRAIN NEOPLASMS; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; GPI-LINKED PROTEINS; HUMANS; IMMUNOLOGIC SURVEILLANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOCITRATE DEHYDROGENASE; KILLER CELLS, NATURAL; MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOME; TUMOR ESCAPE;

EID: 84991392300     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now061     Document Type: Article

References (53)

1. Wu JS, Lever JE. Developmentally regulated 75-kilodalton protein expressed in LLC-PK1 cultures is a component of the renal Na+/ glucose cotransport system. J Cell Biochem. 1989;40(1):83-89.
2. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012; 483(7390):479-483.
3. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cells. 2010;17(1):98-110.
4. Losman JA, Looper R, Koivunen P, et al. (R)-2-Hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339(6127):1621-1625.
5. Turcan S, Fabius AW, Borodovsky A, et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget. 2013;4(10): 1729-1736.
6. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cells. 2011;19(1):17-30.
7. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474-478.
8. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cells. 2006;9(3):157-173.
9. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479-489.
10. Cancer Genome Atlas Research Brat DJ, Verhaak RG, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481-2498.
11. Herberman RB, Nunn ME, Holden HT, et al. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer. 1975;16(2):230-239.
12. Ljunggren HG, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med. 1985;162(6):1745-1759.
13. Algarra I, Cabrera T, Garrido F. The HLA crossroad in tumor immunology. Hum Immunol. 2000;61(1):65-73.
14. French AR, Yokoyama WM. Natural killer cells and viral infections. Curr Opin Immunol. 2003;15(1):45-51.
15. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999; 285(5428):727-729.
16. Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol. 2007;7(9):737-744.
17. Gonzalez S, Groh V, Spies T. Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol. 2006;298:121-138.
18. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene. 2008;27(45):5944-5958.
19. Friese MA, Platten M, Lutz SZ, et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res. 2003;63(24):8996-9006.
20. Eisele G, Wischhusen J, Mittelbronn M, et al. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain. 2006;129(Pt 9): 2416-2425.
21. McGilvray RW, Eagle RA,Watson NF, et al. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res. 2009;15(22): 6993-7002.
22. Duan X, Deng L, Chen X, et al. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol. 2011;28(2):466-474.
23. de Kruijf EM, Sajet A, van Nes JG, et al. NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer. 2012;12:24.
24. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102(4):1389-1396.
25. Baragano Raneros A, Martin-Palanco V, Fernandez AF, et al. Methylation of NKG2D ligands contributes to immune system evasion in acutemyeloid leukemia. Genes Immun. 2015;16(1):71-82.
26. Mamessier E, Sylvain A, Bertucci F, et al. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res. 2011;71(21): 6621-6632.
27. Song H, Kim J, Cosman D, et al. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol. 2006;239(1):22-30.
28. Codo P, Weller M, Meister G, et al. MicroRNA-mediated downregulation of NKG2D ligands contributes to glioma immune escape. Oncotarget. 2014;5(17):7651-7662.
29. de Hoon MJ, Imoto S, Nolan J, et al. Open source clustering software. Bioinformatics. 2004;20(9):1453-1454.
30. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162(1):156-159.
31. Kim GG, Donnenberg VS, Donnenberg AD, et al. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay. J Immunol Methods. 2007; 325(1-2):51-66.
32. Sonoda Y, Ozawa T, Aldape KD, et al. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res. 2001;61(18): 6674-6678.
33. Vivanco I, Palaskas N, Tran C, et al. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cells. 2007;11(6):555-569.
34. Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002;62(21):6178-6186.
35. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197-223.
36. Losman JA, Looper RE, Koivunen P, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339(6127):1621-1625.
37. Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149-1153.
38. Paulick MG, Bertozzi CR. The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. Biochemistry. 2008;47(27):6991-7000.
39. Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001; 14(2):123-133.
40. Gasser S, Raulet DH. Activation and self-tolerance of natural killer cells. Immunol Rev. 2006;214:130-142.
41. Unni AM, Bondar T, Medzhitov R. Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance. Proc Natl Acad Sci U S A. 2008;105(5):1686-1691.
42. Di Tomaso T, Mazzoleni S, Wang E, et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res. 2010;16(3):800-813.
43. Crane CA, Austgen K, Haberthur K, et al. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc Natl Acad Sci U S A. 2014;111(35):12823-12828.
44. Ciaglia E, Torelli G, Pisanti S, et al. Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells. Oncotarget. 2015;6(17):15464-15481.
45. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004; 23(2):255-259.
46. Kernytsky A, Wang F, Hansen E, et al. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood. 2015;125(2):296-303.
47. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340(6132):626-630.
48. Silver DJ, Sinyuk M, Vogelbaum MA, et al. The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities. Neuro Oncol. 2016;18(2):153-159.
49. Okada H, Butterfield LH, Hamilton RL, et al. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res. 2015;21(2):286-294.
50. Walzer T, Dalod M, Vivier E, et al. Natural killer cell-dendritic cell crosstalk in the initiation of immune responses. Expert Opin Biol Ther. 2005;5(Suppl 1):S49-S59.
51. Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512(7514): 324-327.
52. Farmer JP, Antel JP, Freedman M, et al. Characterization of lymphoid cells isolated from human gliomas. J Neurosurg. 1989; 71(4):528-533.
53. Pellegatta S, Valletta L, Corbetta C, et al. Effective immunotargeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun. 2015;3:4.